Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of pembrolizumab + epacadostat versus pembrolizumab + placebo in previously platinum-treated advanced urothelial carcinoma
MOH_2017-12-17_001889Phase 3Not yet recruiting
- Sponsor
- Incyte
- Start
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Pembrolizumab + epacadostat with Pembrolizumab + placebo (2 arms). Planned start Nov 2017; status: not yet recruiting.
02
Drugs
pembrolizumabepacadostat
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2017-12-17_001889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-17_001889.